Your Search Results

Challenging clinical scenarios in STEMI

21 May 2026 – From EuroPCR 2026

This session explores challenging clinical scenarios in STEMI, including coronary embolisation from aortic valve vegetation, blunt chest trauma-related STEMI, intramural hematoma diagnostics with multimodality imaging, acute stent thrombosis during dengue recovery, and advanced clot removal techniques beyond standard aspiration devices.

TAVI in heart failure is possible

21 May 2026 – From EuroPCR 2026

This session demonstrates the feasibility of transcatheter aortic valve implantation (TAVI) in patients with heart failure through a series of challenging cases. It covers sequential management of hypertrophic obstructive cardiomyopathy with aortic stenosis, advanced heart failure interventions, staged approaches in cardiogenic shock, and complex percutaneous interventions...

The pearl of unloading with mechanical circulatory support

21 May 2026 – From EuroPCR 2026

Delve into the critical aspects of mechanical circulatory support in cardiogenic shock, focusing on device selection, assessment of persistent congestion, and the application of unloading tools to improve patient management and outcomes.

The pearl of unloading with mechanical circulatory support

CTO PCI: understand it, love it

21 May 2026 – From EuroPCR 2026

This educational session provides a comprehensive overview of chronic total occlusion (CTO) PCI, elucidating key procedural steps, essential materials, and potential complications. It highlights the significant role of nurses and allied health professionals in supporting the procedure and enhancing patient experience throughout the pre-, intra-, and...

RIVER: Rivaroxaban for valvular heart disease and atrial fibrillation

05 Sep 2023

Alex Sticchi provides his take on the results of the RIVER trial, which were presented by Pedro Gabriel Barros E Silva during the ESC 2023 congress in Amsterdam.

Rivaroxaban versus Warfarin in Patients with Bioprosthetic Valves According to Valvular Heart Disease Etiology, and Thrombotic and Bleeding Risks: Insights from...

Author

Alessandro Sticchi

RIVER: Rivaroxaban for valvular heart disease and atrial fibrillation

Evidence base: current data on TAVI durability and long-term outcomes

22 Jul 2026

This article reviews the current evidence on TAVI durability, focusing on long-term outcomes, device-specific considerations, and the implications for lifetime management strategies.

Author

Tanja Rudolph

Author

Georges El Hachem

Evidence base: current data on durability

SURTAVI: five-year results from a randomized trial of TAVR vs. SAVR in patients at intermediate surgical risk

07 Nov 2021

Although TAVI is an accepted alternative to surgery in patients with severe aortic stenosis who are at high surgical risk, less is known about long-term comparative outcomes among patients with aortic stenosis who are at intermediate surgical risk. P. Redaelli & M. Pighi review the SURTAVI trial...